MiRNAs as biomarkers in colorectal cancer diagnosis and prognosis

Bioanalysis

Volumn 2, Issue 5, 2010, Pages 901-906

  Ju, Jingfang ^a  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; DIHYDROFOLATE REDUCTASE; FLUOROPYRIMIDINE; FLUOROURACIL; HERMES ANTIGEN; K RAS PROTEIN; MICRORNA; MICRORNA 140; MICRORNA 143; MICRORNA 145; MICRORNA 192; MICRORNA 200C; MICRORNA 21; MICRORNA 215; MICRORNA 24; MICRORNA 26A; MICRORNA 29A; PROTEIN P53; RNA; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CELL CYCLE REGULATION; COLORECTAL CANCER; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GOLD STANDARD; HUMAN; MICROARRAY ANALYSIS; NORTHERN BLOTTING; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; RNA STABILITY; SENSITIVITY AND SPECIFICITY; ANIMAL; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ANIMALS; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PROGNOSIS; RNA STABILITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952520038     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.10.45     Document Type: Review

References (57)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806-811 (1998). (Pubitemid 28099681)
2. Lee RC, Feinbaum RL, and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993). (Pubitemid 24014542)
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer. 6, 259-269 (2006).
5. Cummins JM, He Y, Leary RJ et al. The colorectal microRNAome. Proc. Natl Acad. Sci. USA 103, 3687-3692 (2006). (Pubitemid 43376616)
6. Pillai RS, Bhattacharyya SN, Artus CG et al. Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science 309, 1573-1576 (2005). (Pubitemid 41266485)
7. Ruvkun G. Clarifications on miRNA and cancer. Science 311, 36-37 (2006).
8. Dony C, Kessel M, Gruss P. Post-transcriptional control of myc and p53 expression during differentiation of the embryonal carcinoma cell line F9. Nature 317, 636-639 (1985). (Pubitemid 16222537)
9. Barad O, Meiri E, Avniel A et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res. 14, 2486-2494 (2004). (Pubitemid 40012232)
10. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101, 11755-11760 (2004). (Pubitemid 39095368)
11. Babak T, Zhang W, Morris Q, Blencowe BJ, Hughes TR. Probing microRNAs with microarrays: tissue specificity and functional inference. RNA 10, 1813-1819 (2004). (Pubitemid 39426380)
12. Miska EA, Alvarez-Saavedra E, Townsend M et al. Microarray analysis of microRNA expression in the developing mammalian brain. Genome Biol. 5, R68 (2004).
13. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat. Methods. 1, 155-161 (2004).
14. Liu CG, Calin GA, Meloon B et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl Acad. Sci. USA 101, 9740-9744 (2004). (Pubitemid 38869306)
15. Chen C, Ridzon DA, Broomer AJ et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33, E179 (2005).
16. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005). (Pubitemid 40839735)
17. Nuovo G, Lee EJ, Lawler S, Godlewski J, Schmittgen T. In situ detection of mature microRNAs by labeled extension on ultramer templates. Biotechniques 46, 115-126 (2009).
18. Nuovo GJ, Elton TS, Nana-Sinkam P, Volinia S, Croce CM, Schmittgen TD. A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat. Protoc. 4, 107-115 (2009).
19. Neely LA, Patel S, Garver J et al. A single-molecule method for the quantitation of microRNA gene expression. Nat. Methods. 3, 41-46 (2006). (Pubitemid 43135348)
20. Creighton CJ, Reid JG, Gunaratne PH. Expression profiling of microRNAs by deep sequencing. Brief Bioinform. 10, 490-497 (2009).
21. Lee EJ, Baek M, Gusev Y, Brackett DJ, Nuovo GJ, Schmittgen TD. Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. RNA 14, 35-42 (2008).
22. Jiang J, Lee EJ, Gusev Y, Schmittgen TD. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 33, 5394-5403 (2005). (Pubitemid 41548806)
23. Sato F, Tsuchiya S, Terasawa K, Tsujimoto G. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One. 4, E5540 (2009).
24. Xi Y, Nakajima G, Gavin E et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13, 1668-1674 (2007). (Pubitemid 47481675)
25. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
26. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer DOI: 10.1002/ijc.25007 (2009) (Epub ahead of print).
27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J. Clin. 59, 225-249 (2009).
28. Weisenberger DJ, Siegmund KD, Campan M et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet. 38, 787-793 (2006). (Pubitemid 43980599)
29. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157-158 (2007). (Pubitemid 46184343)
30. Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 66, 7390-7394 (2006). (Pubitemid 44289189)
31. Ju J, Pedersen-Lane J, Maley F, Chu E. Regulation of p53 expression by thymidylate synthase. Proc. Natl Acad. Sci. USA 96, 3769-3774 (1999). (Pubitemid 29168985)
32. Fu L, Minden MD, Benchimol S. Translational regulation of human p53 gene expression. EMBO J. 15, 4392-4401 (1996). (Pubitemid 26278720)
33. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 99, 15524-15529 (2002). (Pubitemid 35403967)
34. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1, 882-891 (2003). (Pubitemid 37288707)
35. Chen X, Guo X, Zhang H et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 28, 1385-1392 (2009).
36. Xi Y, Shalgi R, Fodstad O, Pilpel Y, Ju J. Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin. Cancer Res. 12, 2014-2024 (2006).
37. He L, He X, Lim LP et al. A microRNA component of the p53 tumour suppressor network. Nature 447, 1130-1134 (2007). (Pubitemid 47014436)
38. Chang TC, Wentzel EA, Kent OA et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 26, 745-752 (2007). (Pubitemid 46856245)
39. Raver-Shapira N, Marciano E, Meiri E et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 26, 731-743 (2007). (Pubitemid 46856247)
40. Song B, Wang Y, Kudo K, Gavin EJ, Xi Y, Ju J. miR-192 regulates dihydrofolate reductase and cellular proliferation through the p53-microRNA circuit. Clin. Cancer Res. 14, 8080-8086 (2008).
41. Georges SA, Biery MC, Kim SY et al. Coordinated regulation of cell cycle transcripts by p53-inducible microRNAs, miR-192 and miR-215. Cancer Res. 68, 10105-10112 (2008).
42. Braun CJ, Zhang X, Savelyeva I et al. p53-responsive microRNAs 192 and 215 are capable of inducing cell cycle arrest. Cancer Res. 68, 10094-10104 (2008).
43. Ju J, Song B, Wang Y. Impacts of microRNA-215 on cell proliferation and chemotherapy resistance in colon cancer and osteosarcoma (2009 ASCO Annual Meeting Proceedings).J. Clin. Oncol. 27(15S), 2542 (2009).
44. Mishra PJ, Humeniuk R, Mishra PJ, Longo-Sorbello GS, Banerjee D, Bertino JR. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance. Proc. Natl Acad. Sci. USA 104, 13513-13518 (2007). (Pubitemid 47293976)
45. Mishra PJ, Song B, Wang Y et al. MiR-24 tumor suppressor activity is regulated independent of p53 and through a target site polymorphism. PLoS One, 4, E8445 (2009).
46. Lal A, Navarro F, Maher CA et al. miR-24 inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to 'seedless' 3́UTR microRNA recognition elements. Mol. Cell 35, 610-625 (2009).
47. Ji J, Shi J, Budhu A et al. MicroRNA expression, survival, and response to interferon in liver cancer. N. Engl. J. Med. 361, 1437-1447 (2009).
48. Kota J, Chivukula RR, O'Donnell KA et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137, 1005-1017 (2009).
49. Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28, 4065-4074 (2009).
50. Ng EK, Chong WW, Jin H et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 58, 1375-1381 (2009).
51. Nakajima G, Hayashi K, Xi Y et al. Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 3, 317-324 (2006). (Pubitemid 44701551)
52. Schepeler T, Reinert JT, Ostenfeld MS et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res. 68, 6416-6424 (2008).
53. Xi Y, Formentini A, Chien M et al. Prognostic values of microRNAs in colorectal cancer. Biomark. Insights 2, 113-121 (2006).
54. Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10, 593-601 (2008). (Pubitemid 351627379)
55. Peter ME. Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle 8, 843-852 (2009).
56. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299, 425-436 (2008). (Pubitemid 351185951)
57. Slaby O, Svoboda M, Fabian P et al. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 72, 397-402 (2007). (Pubitemid 351238155)